Global Neuroscience Market - 2025-2033

The global neuroscience market reached US$ 44.6 billion in 2024 and is expected to reach US$ 73.5 billion by 2033, growing at a CAGR of 5.7% during the forecast period 2025-2033.

Neuroscience is a multidisciplinary field of science that focuses on the study of the structure, function, development, genetics, biochemistry, physiology, and pathology of the nervous system. The primary aim of neuroscience is to understand the complex systems of the brain and spinal cord and how they interact to control behavior, cognition, emotions, memory, perception, and other physiological functions. Neuroscience relies on a variety of techniques and tools, including neuroimaging, electrophysiology, molecular biology, genetics, and computational modeling to explore these intricate aspects of brain function and to develop new approaches to treat brain-related disorders.

The neuroscience market is experiencing significant growth, driven by advancements in technology, increasing prevalence of neurological disorders, and rising research investments in the field of neuroscience. For instance, in January 2025, BrainSight AI secured $5 million in funding in a pre-series A investment round. With intentions to expand into India and seek FDA clearance. The company intends to reach US markets and investigate potential in Africa and Southeast Asia. Its product package comprises Voxelbox and Snowdrop, which promise to improve brain disorder diagnosis and patient care.

Market Dynamics: Drivers & Restraints

Rising technological advancements in neuroscience

The rising technological advancements in neuroscience are significantly driving the growth of the neuroscience market and are expected to drive the market over the forecast period. Neuroimaging techniques such as functional Magnetic Resonance Imaging (fMRI), Positron Emission Tomography (PET), and Electroencephalography (EEG) are advancing rapidly. These technologies enable better visualization of brain activity, helping researchers understand the underlying causes of neurological disorders and improving diagnostic accuracy.

For instance, in August 2024, Natus Medical Incorporated launched autoSCORE, the first artificial intelligence model capable of automatically and comprehensively interpreting clinical EEG data with accuracy comparable to medical specialists. Holberg EEG developed the autoSCORE program in Norway, employing a deep-learning model and training on the world's largest dataset of over 30,000 carefully annotated EEG recordings. The autoSCORE application has the potential to enhance clinical outcomes and healthcare value for millions of people suffering from epilepsy.

Additionally, AI-driven solutions are expected to play a significant role in the growing neuroscience market. AI applications, especially in the areas of brain imaging, disease diagnosis, and personalized treatments, are likely to revolutionize the healthcare and drug development sectors.

For instance, in February 2024, Royal Philips introduced Smart Quant Neuro 3D, a significant advancement in objective decision support for the diagnosis and therapy assessment of brain disorders such as multiple sclerosis (MS), traumatic brain injury (TBI), and dementia. Smart Quant Neuro 3D combines Philips' AI-powered SmartSpeed image reconstruction technology, the Philips 3D SyntAc clinical application, and Synthetic MR's SyMRI NEURO 3D quantitative tissue assessment software. The integrated solution provides healthcare providers with powerful tools for increased diagnostic confidence, which ultimately benefits patients.

Limited treatment options for rare neurological disorders

The limited treatment options for rare neurological disorders are expected to hamper the growth of the neuroscience market. These disorders, which affect a small number of patients, often lack effective treatments due to various challenges in research, drug development, and market incentives. Conditions like Huntington's disease, Amyotrophic Lateral Sclerosis (ALS) and Cerebral Palsy often receive less attention from drug manufacturers, slowing progress in developing new therapies. Although some research is being conducted, these diseases remain difficult to treat due to the complexity of the brain and nervous system.

With rare neurological disorders, the small number of patients makes it difficult to recruit participants for clinical trials. This hampers the progress of drug development as pharmaceutical companies struggle to meet the requirements for large-scale, statistically significant trials. For instance, trials for rare neurogenetic diseases such as Rett syndrome or Fragile X syndrome face challenges in recruiting participants, slowing down the development of potential therapies.

Segment Analysis

The global neuroscience market is segmented based on type, component, technology, end-user and region.

Technology:

The brain imaging segment is expected to dominate the neuroscience market share

Brain imaging techniques such as MRI (Magnetic Resonance Imaging), CT (Computed Tomography), fMRI (functional MRI), and PET (Positron Emission Tomography) are indispensable in diagnosing neurological disorders, including Alzheimer's, Parkinson's, epilepsy, and brain tumors. These technologies provide non-invasive, high-resolution insights into brain structure and function.

For instance, in November 2024, Hyperfine, Inc., the pioneering health technology company that revolutionized brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system, the Swoop system, announced CE approval of its latest generation of AI-powered Swoop system software under the European Medical Device Regulation (MDR, EU No. 2017/745). This certification is a crucial step toward Hyperfine's broad European rollout of the Swoop Portable MR Imaging system, which enables faster, high-quality MR brain imaging to assist critical diagnostic choices across a variety of healthcare settings.

Emerging technologies like 3D imaging, AI-assisted image analysis, and quantitative imaging biomarkers are enhancing the precision and efficiency of brain imaging. These advancements allow early diagnosis, improved treatment monitoring, and better research outcomes. AI-integrated imaging tools are used to quickly detect and prioritize brain disorders, saving critical time in treatment.

For instance, in December 2024, GE HealthCare introduced Sonic DL for 3D, the latest addition to their easy imaging portfolio, which is intended to expedite MRI scans in a variety of clinical applications. Sonic DL for 3D draws on GE HealthCare's deep learning innovation legacy and the success of AIR Recon DL, which has assisted more than 34 million patients to date. This extension is expected to maintain the same outstanding 12x acceleration while reducing scan times by up to 86%.

Geographical Analysis

North America is expected to hold a significant position in the neuroscience market share

North America especially the United States leads in the adoption and integration of cutting-edge neuroscience technologies, such as neuroimaging, neurostimulation and artificial intelligence (AI) in the diagnosis and treatment of neurological conditions. The U.S. market is characterized by the rapid adoption of new technologies due to significant investments in innovation and a strong patenting ecosystem. Companies like Medtronic and Boston Scientific are pioneering innovations in neurostimulation devices and other neurotherapeutic products in North America. Similarly, AI applications in neuroimaging are gaining traction for faster, more accurate diagnoses.

For instance, in December 2024, Medtronic gained FDA approval for its Percept RC, which is currently accessible in India. According to the firm, this is the smallest and thinnest two channel neurostimulator available for Deep Brain Stimulation (DBS) systems, representing the most recent improvement in the Percept series. The Percept RC is equipped with BrainSense technology, which detects and records brain signals, providing vital insights that allow healthcare practitioners to adjust and personalize therapy to match each patient's changing needs.

Leading companies such as Eli Lilly, Biogen, Neurocrine Biosciences, and Medtronic and other emerging players such as Neurable Inc. and others are based in North America mostly in the United States and are instrumental in the development of groundbreaking treatments and devices for neurological diseases. These companies contribute to both the research and commercialization of new therapies, advanced devices and technologies for neurological disorders.

For instance, in September 2024, Neurable Inc. introduced the MW75 Neuro, smart headphones that include Neurable's brain-computer interface (BCI) technology to enable users to receive deeper insights into their cognitive health, control burnout, and improve everyday performance. These headphones, the first BCI-enabled consumer-grade item of their type, are poised to transform how we engage with daily technology by allowing users to regulate their health and well-being using the power of their minds.

Asia-Pacific is growing at the fastest pace in the neuroscience market

Asia-Pacific especially India, Japan and China is rapidly adopting new technologies in healthcare, including AI-assisted imaging, neurostimulation devices, and advanced diagnostic tools. This has enhanced the region's capabilities in diagnosing and treating neurological disorders more efficiently. Additionally, companies and hospitals in APAC are also developing advanced and affordable neurostimulation devices for neurological conditions.

For instance, in April 2024, JK Physio and Rehab Clinic announced the debut of the groundbreaking Advanced Exoskeletal Neuro Device, which will revolutionize neurorehabilitation in India. This nerve stimulation device allows complete spinal and muscular mobility, resulting in speedier recovery for both totally and partially paralyzed patients.

Additionally, in November 2023, RapidAI, a health tech firm that specializes in image analysis software, said that it has acquired Class III Shonin approval in Japan and has released a hybrid technology platform called Rapid Edge Cloud, as well as a non-contrast CT product for stroke detection. It offers digital platforms that allow hospital care teams and EMS providers to coordinate treatment, analytics software that helps hospitals run more efficiently, and a clinical trial platform that streamlines the clinical trial screening and enrollment process.

Competitive Landscape

The major global players in the neuroscience market include GE HealthCare, Medtronic plc, F. Hoffmann-La Roche Ltd., Siemens Healthcare Private Limited, B. Braun Melsungen AG, Stryker Corporation, Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Bio-Rad Laboratories, Inc. and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Neuroscience market report delivers a detailed analysis with 70 key tables, more than 71 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.